Pharmacokinetics of cefovecin in cynomolgus Macaques (Macaca fascicularis), olive baboons (Papio anubis), and rhesus macaques (Macaca mulatta)

Journal of the American Association for Laboratory Animal Science

Volumn 50, Issue 3, 2011, Pages 389-395

  Raabe, Brigitte M ^a,e   Lovaglio, Jamie ^a,b   Grover, G Scott ^c   Brown, Scott A ^c   Boucher, Joseph F ^c   Yuan, Yang ^c   Civil, Jacqueline R ^c   Gillhouse, Kimberly A ^d   Stubbs, Makeida N ^d   Hoggatt, Amber F ^a   Halliday, Lisa C ^a   Fortman, Jeffrey D ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c ZOETIS   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOVECIN; VETERINARY DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; FEMALE; KIDNEY CLEARANCE; KIDNEY TUBULE ABSORPTION; MACACA FASCICULARIS; MACACA MULATTA; MALE; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PAPIO ANUBIS; PLASMA CLEARANCE; PLASMA PROTEIN BINDING; SIMULATION; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ANIMALS; ANIMALS, LABORATORY; ANTI-INFECTIVE AGENTS; CEPHALOSPORINS; FEMALE; GLOMERULAR FILTRATION RATE; HALF-LIFE; MACACA FASCICULARIS; MACACA MULATTA; MALE; MONKEY DISEASES; PAPIO ANUBIS; SKIN DISEASES; SPECIES SPECIFICITY;

CANIS FAMILIARIS; MACACA; MACACA FASCICULARIS; MACACA MULATTA; PAPIO ANUBIS; PRIMATES;

EID: 79960640167     PISSN: 15596109     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Animal Welfare Act Regulations. 2008. 9 CFR § 3.75-3.85.
2. Birrell AM, Heffernan SJ, Kirwan P, McLennan S, Gillin AG, Yue DK. 2002. The effects of aminoguanidine on renal changes in a baboon model of Type 1 diabetes. J Diabetes Complications 16:301-309. (Pubitemid 34765729)
3. Butler TM, Brown BG, Dysko RC, Ford EW, Hoskins DE, Klein HJ, Levin JL, Murray KA, Rosenberg DP, Southers JL, Swenson RB. 1995. Medical management, p 255-334. In: Bennett BT, Abee CR, Henrickson R, editors. Nonhuman primates in biomedical research: biology and management. San Diego (CA): Academic Press.
4. Craig WA. 1998. Pharmacokinetic-pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-12. (Pubitemid 28068148)
5. Ebert SC. 2004. Application of pharmacokinetics and pharmcodynamics to antibiotic selection. P T 29:244-250. (Pubitemid 38543509)
6. Fekety RF. 1990. Safety of parenteral third-generation cephalosporins. Am J Med 88:38S-44S.
7. Institute for Laboratory Animal Research. 1996. Guide for the care and use of laboratory animals. Washington (DC): National Academies Press.
8. Leggett JE, Fantin B, Ebert S, Totsuka K, Vogelman B, Calame W, Mattie H, Craig WA. 1989. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 159:281-292. (Pubitemid 19049368)
9. McKellar QA, Sanchez Bruni SF, Jones DG. 2004. Pharmacokinetic- pharmacodynamic relationship of antimicrobial drugs used in veterinary medicine. J Vet Pharmacol Ther 27:503-514. (Pubitemid 39665136)
10. Papp R, Popovic A, Kelly N, Tschirret-Guth R. 2010. Pharmacokinetics of cefovecin in squirrel monkey (Saimiri sciureus), rhesus macaques (Macaca mulatta), and cynomolgus macaques (Macaca fascicularis). J Am Assoc Lab Anim Sci 49:805-808.
11. Pfizer Animal Health. 2008. Convenia package insert. New York (NY).
12. Plumb DC, editor. 2002. Veterinary drug handbook, 4th edition. Ames (IA): Blackwell Publishing.
13. Schaer GL, Fink MP, Chernow B, Ahmed S, Parrillo JE. 1990. Renal hemodynamics and prostaglandin E2 excretion in a nonhuman primate model of septic shock. Crit Care Med 18:52-59. (Pubitemid 20039156)
14. Stegemann MR, Passmore CA, Sherington J, Lindeman CJ, Papp G, Weigel DJ, Skogerboe TL. 2006. Antimicrobial activity and spectrum of cefovecin, a new extended-spectrum cephalosporin, against pathogens collected from dogs and cats in Europe and North America. Antimicrob Agents Chemother 50:2286-2292. (Pubitemid 43996783)
15. Stegemann MR, Sherington J, Blanchflower S. 2006. Pharmacokinetics and pharmacodynamics of cefovecin in dogs. J Vet Pharmacol Ther 29:501-511. (Pubitemid 44684093)
16. Stegemann MR, Sherington J, Coati N, Brown SA, Blanchflower S. 2006. Pharmacokinetics of cefovecin in cats. J Vet Pharmacol Ther 29:513-524. (Pubitemid 44684094)
17. Taft DR. 2009. Drug excretion, p 175-199. In: Hacker M, Bachmann K, Messer W, editors. Pharmacology in principles and practice. San Deigo (CA): Academic Press.
18. United States Department of Health and Human Services, Food and Drug Administration. 2001. Guidance for industry: bioanalytical method validation. Washington (DC): United States Department of Health and Human Services.
19. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. 1988. Correlation of antimicrobial pharmacokinetics parameters with therapeutic efficacy in an animal model. J Infect Dis 158:831-847.